Under the agreement, NRG PALLAS and TAG1, Inc. will collaborate to produce critical isotopes including radium-224 and its daughter isotope, lead-212. Lead-212 is increasingly recognized for its role in TATs, offering precision treatments by delivering potent alpha particles directly to cancerous cells while sparing healthy tissue. This innovative collaboration will bolster the availability of critical isotopes, supporting the development and delivery of life-saving therapies to cancer patients.

Vinod Ramnandanlal, Commercial Director of NRG PALLAS: “Together, we are fortifying the future accessibility and scalability of vital medical isotopes required to develop life-saving therapies. This partnership secures a reliable supply chain for these critical isotopes, supporting advancements in clinical applications and commercial efforts, and helping to shape the future of cancer care."

Sumit Verma, CEO of TAG1, Inc.: “We are thrilled to announce our partnership with NRG PALLAS. This organization continues to be a leader in the production of key isotopes, and this relationship has the potential to be a game-changer in Targeted Alpha Therapies (TATs). This agreement strengthens both company’s ability to make a measurable difference in patient lives and will further position TAG1 as a premier supplier for the radiopharma industry. We look forward to contributing towards innovative cancer therapies that can improve patient outcomes globally.”